158 related articles for article (PubMed ID: 8033529)
1. Effect of sulphonylurea therapy on plasma insulin, intact and 32/33 split proinsulin in subjects with type 2 diabetes mellitus.
Davies MJ; Metcalfe J; Day JL; Grenfell A; Hales CN; Gray IP
Diabet Med; 1994 Apr; 11(3):293-8. PubMed ID: 8033529
[TBL] [Abstract][Full Text] [Related]
2. The effect of gliclazide on plasma insulin, intact and 32/33 split proinsulin in South Asian subjects with Type 2 diabetes mellitus.
Ammari F; Davies MJ; Koppiker N; Gregory R; Burden AC
Diabet Med; 1999 Feb; 16(2):142-6. PubMed ID: 10229308
[TBL] [Abstract][Full Text] [Related]
3. Improved beta cell function, with reduction in secretion of intact and 32/33 split proinsulin, after dietary intervention in subjects with type 2 diabetes mellitus.
Davies MJ; Metcalfe J; Day JL; Grenfell A; Hales CN; Gray IP
Diabet Med; 1994; 11(1):71-8. PubMed ID: 8181257
[TBL] [Abstract][Full Text] [Related]
4. Increased secretion of 32,33 split proinsulin after intravenous glucose in glucose-tolerant first-degree relatives of patients with non-insulin dependent diabetes of European, but not Asian, origin.
Gelding SV; Andres C; Niththyananthan R; Gray IP; Mather H; Johnston DG
Clin Endocrinol (Oxf); 1995 Mar; 42(3):255-64. PubMed ID: 7758230
[TBL] [Abstract][Full Text] [Related]
5. Immunoradiometric assay of insulin, intact proinsulin and 32-33 split proinsulin and radioimmunoassay of insulin in diet-treated type 2 (non-insulin-dependent) diabetic subjects.
Clark PM; Levy JC; Cox L; Burnett M; Turner RC; Hales CN
Diabetologia; 1992 May; 35(5):469-74. PubMed ID: 1521730
[TBL] [Abstract][Full Text] [Related]
6. Insulin deficiency rather than hyperinsulinaemia in newly diagnosed type 2 diabetes mellitus.
Davies MJ; Metcalfe J; Gray IP; Day JL; Hales CN
Diabet Med; 1993 May; 10(4):305-12. PubMed ID: 8508611
[TBL] [Abstract][Full Text] [Related]
7. Effects of antihyperglycaemic therapies on proinsulin and relation between proinsulin and cardiovascular risk factors in type 2 diabetes.
Hermann LS; Ranstam J; Vaaler S; Melander A
Diabetes Obes Metab; 1999 Jul; 1(4):227-32. PubMed ID: 11228758
[TBL] [Abstract][Full Text] [Related]
8. Intact proinsulin, des 31,32 proinsulin, and specific insulin concentrations among nondiabetic and diabetic subjects in populations at varying risk of type 2 diabetes.
Nagi DK; Knowler WC; Mohamed-Ali V; Bennett PH; Yudkin JS
Diabetes Care; 1998 Jan; 21(1):127-33. PubMed ID: 9538983
[TBL] [Abstract][Full Text] [Related]
9. Serum lipoprotein levels and plasma concentrations of insulin, intact and 32, 33 split proinsulin in normoglycaemic relatives of patients with type 2 diabetes.
Gelding SV; Andres C; Niththyananthan R; Richmond W; Gray IP; Johnston DG
Diabet Med; 1994 Oct; 11(8):748-54. PubMed ID: 7851068
[TBL] [Abstract][Full Text] [Related]
10. Insulin deficiency and increased plasma concentration of intact and 32/33 split proinsulin in subjects with impaired glucose tolerance.
Davies MJ; Rayman G; Gray IP; Day JL; Hales CN
Diabet Med; 1993 May; 10(4):313-20. PubMed ID: 8508612
[TBL] [Abstract][Full Text] [Related]
11. Is the defect in pro-hormone processing in Type 2 diabetes mellitus restricted to the beta cell?
Bano G; Rodin DA; White A; O'Rahilly S; Nussey SS
Diabet Med; 2001 Jan; 18(1):17-21. PubMed ID: 11168336
[TBL] [Abstract][Full Text] [Related]
12. Fasting proinsulin concentrations predict the development of type 2 diabetes.
Wareham NJ; Byrne CD; Williams R; Day NE; Hales CN
Diabetes Care; 1999 Feb; 22(2):262-70. PubMed ID: 10333943
[TBL] [Abstract][Full Text] [Related]
13. Normal proinsulin processing despite beta-cell dysfunction in persistent hyperinsulinaemic hypoglycaemia of infancy (nesidioblastosis).
Leibowitz G; Weintrob N; Pikarsky A; Josefsberg Z; Landau H; Glaser B; Hales CN; Cerasi E
Diabetologia; 1996 Nov; 39(11):1338-44. PubMed ID: 8933002
[TBL] [Abstract][Full Text] [Related]
14. Different effects of acarbose and glibenclamide on proinsulin and insulin profiles in people with Type 2 diabetes.
Hanefeld M; Haffner SM; Menschikowski M; Koehler C; Temelkova-Kurktschiev T; Wildbrett J; Fischer S
Diabetes Res Clin Pract; 2002 Mar; 55(3):221-7. PubMed ID: 11850098
[TBL] [Abstract][Full Text] [Related]
15. Effect of sulfonylurea withdrawal on proinsulin levels, B cell function, and glucose disposal in subjects with noninsulin-dependent diabetes mellitus.
Prigeon RL; Jacobson RK; Porte D; Kahn SE
J Clin Endocrinol Metab; 1996 Sep; 81(9):3295-8. PubMed ID: 8784086
[TBL] [Abstract][Full Text] [Related]
16. UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group.
Matthews DR; Cull CA; Stratton IM; Holman RR; Turner RC
Diabet Med; 1998 Apr; 15(4):297-303. PubMed ID: 9585394
[TBL] [Abstract][Full Text] [Related]
17. Compared to glibenclamide, repaglinide treatment results in a more rapid fall in glucose level and beta-cell secretion after glucose stimulation.
Abbink EJ; van der Wal PS; Sweep CG; Smits P; Tack CJ
Diabetes Metab Res Rev; 2004; 20(6):466-71. PubMed ID: 15386823
[TBL] [Abstract][Full Text] [Related]
18. Hyperproinsulinemia is not a characteristic feature in the offspring of patients with different phenotypes of type II diabetes.
Vauhkonen IK; Niskanen LK; Mykkänen L; Haffner SM; Uusitupa MI; Laakso M
Eur J Endocrinol; 2000 Aug; 143(2):251-60. PubMed ID: 10913945
[TBL] [Abstract][Full Text] [Related]
19. United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years.
BMJ; 1995 Jan; 310(6972):83-8. PubMed ID: 7833731
[TBL] [Abstract][Full Text] [Related]
20. Sulphonylurea therapy doubles B-cell response to glucose in type 2 diabetic patients.
Hosker JP; Burnett MA; Davies EG; Harris EA; Turner RC
Diabetologia; 1985 Nov; 28(11):809-14. PubMed ID: 3936738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
